Advance Report: Insulin degludec and hypoglycaemia

First published June 2016, updated March 2022   New results from two phase 3b trials have shown that type 1 and type 2 diabetes patients treated with insulin degludec (Tresiba) experience significantly lower rates of several types of hypoglycaemia, compared with patients treated with insulin glargine U100. The findings are important for people with diabetes, as fear of hypoglycaemia or ‘hypos’ is a common problem and a feeling that is often shared by their friends and loved ones. On average, people with type 1 diabetes experience two episodes of symptomatic hypoglycaemia per week and for people with type 2 diabetes,